Expert Analysis

Early Breast Cancer: Chemotherapy and Targeted Agents

Source: CCO Independent Conference Coverage of the CCO Independent Conference Coverage of the 2007 San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Early Breast Cancer: Chemotherapy and Targeted Agents

Faculty:

Howard A. Burris III, MD
William J. Gradishar, MD, FACP
Edith A. Perez, MD

CREDIT INFORMATION

Release Date: February 25, 2008

Expiration Date: February 24, 2009

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing contact hours

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the use of genetic signature assays to determine which breast cancer patients might benefit from specific therapeutic modalities
Cite the use of anthracyclines as adjuvant treatment for breast cancer
Describe the role of biologic and targeted agents in the treatment of breast cancer

Topics covered include:

21-Gene Recurrence Score Assay in Node-Positive, ER-Positive Breast Cancer
Anthracyclines as Adjuvant Treatment for Breast Cancer
Docetaxel/Cyclophosphamide vs Doxorubicin/Cyclophosphamide
Addition of Adjuvant Bevacizumab to Anthracycline-Containing Regimens
3-Year Follow-up of Trastuzumab Following Adjuvant Chemotherapy
HER2 and Polysomy 17: Outcomes With Trastuzumab
High-Dose Chemotherapy Regimens Combined With Autologous Stem Cell Transplantation
Effects of Denosumab Therapy on Bone Mineral Density
Concluding Remarks

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.